Abstract: The present invention relates to a lipid system which not only improves stability during digestion and oral bioavailability of various bioactive compounds in a safe and effective manner, but also in many cases enhances the effects of said compounds. The present invention also relates to formulations or compositions comprising lipid systems carrying bioactive compounds for use as immunotherapy potentiators or adjuvants for patients with cancer or immunological disorders.

Abstract: The present disclosure provides compositions comprising a supercritical rosemary extract and a lipid system comprising raffish liver oil or the product of an enzymatic or chemical glycerolysis processing of ratfish liver oil. The present disclosure also provides use of said compositions for immunotherapy potentiators or adjuvants for patients with cancer or immunological disorders; treatment of autoimmune-based immunological disorder selected from the group consisting of: rheumatoid arthritis, type I diabetes, psoriasis, celiac disease and multiple sclerosis; treatment of tumor growth, chronic lymphocytic choriomeningitis virus infection, hepatitis (B and C) virus infection, or human immunodeficiency virus infection; or prevention of kidney damage.

Abstract: The present invention relates to the use of apolipoprotein A, a mimetic peptide thereof, or an activator thereof for the preparation of a medicinal product for the treatment or prevention of cancer. The invention also relates to a method for determining the stage of a colorectal tumor in a patient, where the method comprises determining ApoA1 levels in a biofluid from said patient, wherein decreased ApoA1 levels with respect to a reference value indicate a more advanced stage of the tumor, as well as a method for selecting treatment for a cancer patient, where the method comprises determining ApoA1 levels in a biofluid from said patients, wherein decreased ApoA1 levels with respect to a reference value indicate that the therapy of choice is a therapy based on apolipoprotein A, a mimetic peptide thereof, or an activator thereof.

Abstract: The present invention relates to a lipid system which not only improves stability during digestion and oral bioavailability of various bioactive compounds in a safe and effective manner, but also in many cases enhances the effects of said compounds. The present invention also relates to formulations or compositions comprising lipid systems carrying bioactive compounds for use as immunotherapy potentiators or adjuvants for patients with cancer or immunological disorders.

Abstract: The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent or a death receptor ligand and uses thereof for the treatment of cancer.

Abstract: The present invention relates to methods for the treatment of cancer based on the induction of the choline kinase beta (hereinafter ChoK?) activity as well as to methods for the design of personalized therapies and for determining the response of an agent capable of inducing choline kinase beta (hereinafter ChoK?) for the treatment of cancer as well as to methods for determining the prognosis of a patient based on the determination of the ChoK? expression levels as well as based on the determination of the relationship between the ChoK? and ChoK? expression levels. Finally, the invention relates to methods for determining the response of a patient who suffers from cancer to ChoK?-inhibiting agents based on the determination of the PEMT and/or ChoK? expression levels.

Abstract: The present invention relates to an in vitro method for identifying and evaluating compounds useful in the treatment of different types of cancer, especially lung, breast, colorectal and bladder cancer in an individual, for determining the stage or severity of said cancer in the individual, or for monitoring the effect of the therapy administered to an individual having said cancer; to finding, identifying, developing and evaluating the efficacy of compounds for the therapy of said cancer, for the purpose of developing new medicinal products; as well as to agents inhibiting the expression and/or activity of the choline kinase alpha protein and/or the effects of this expression.

Abstract: The present invention relates to an in vitro method for identifying and evaluating compounds useful in the treatment of different types of cancer, especially lung, breast, colorectal and bladder cancer in an individual, for determining the stage or severity of said cancer in the individual, or for monitoring the effect of the therapy administered to an individual having said cancer; to finding, identifying, developing and evaluating the efficacy of compounds for the therapy of said cancer, for the purpose of developing new medicinal products; as well as to agents inhibiting the expression and/or activity of the choline kinase alpha protein and/or the effects of this expression.

Abstract: The present invention relates to an in vitro method for identifying and evaluating compounds useful in the treatment of different types of cancer, especially lung, breast, colorectal and bladder cancer in an individual, for determining the stage or severity of said cancer in the individual, or for monitoring the effect of the therapy administered to an individual having said cancer; to finding, identifying, developing and evaluating the efficacy of compounds for the therapy of said cancer, for the purpose of developing new medicinal products; as well as to agents inhibiting the expression and/or activity of the choline kinase alpha protein and/or the effects of this expression.

Abstract: The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent or a death receptor ligand and uses thereof for the treatment of cancer.

Abstract: The present invention relates to an in vitro method for identifying and evaluating compounds useful in the treatment of different types of cancer, especially lung, breast, colorectal and bladder cancer in an individual, for determining the stage or severity of said cancer in the individual, or for monitoring the effect of the therapy administered to an individual having said cancer; to finding, identifying, developing and evaluating the efficacy of compounds for the therapy of said cancer, for the purpose of developing new medicinal products; as well as to agents inhibiting the expression and/or activity of the choline kinase alpha protein and/or the effects of this expression.

Abstract: The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and a chemotherapeutic agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and a death receptor ligand and uses thereof for the treatment of cancer.

Abstract: The present invention relates to methods for the treatment of cancer based on the induction of the choline kinase beta (hereinafter ChoK?) activity as well as to methods for the design of personalized therapies and for determining the response of an agent capable of inducing choline kinase beta (hereinafter ChoK?) for the treatment of cancer as well as to methods for determining the prognosis of a patient based on the determination of the ChoK? expression levels as well as based on the determination of the relationship between the ChoK? and ChoK? expression levels. Finally, the invention relates to methods for determining the response of a patient who suffers from cancer to ChoK?-inhibiting agents based on the determination of the PEMT and/or ChoK? expression levels.

Abstract: The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent or a death receptor ligand and uses thereof for the treatment of cancer.

Abstract: The present invention relates to an in vitro method for identifying and evaluating compounds useful in the treatment of different types of cancer, especially lung, breast, colorectal and bladder cancer in an individual, for determining the stage or severity of said cancer in the individual, or for monitoring the effect of the therapy administered to an individual having said cancer; to finding, identifying, developing and evaluating the efficacy of compounds for the therapy of said cancer, for the purpose of developing new medicinal products; as well as to agents inhibiting the expression and/or activity of the choline kinase alpha protein and/or the effects of this expression.